Clinical Trial Detail

NCT ID NCT03111901
Title Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors William Grosh, MD
Indications

melanoma

renal cell carcinoma

Therapies

Aldesleukin + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.